A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
Latest Information Update: 11 Nov 2025
At a glance
- Drugs BGM 1812 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors BrightGene Bio-medical technology
Most Recent Events
- 11 Nov 2025 New trial record